

# Pr **DOJOLVI**<sup>®</sup>

## Triheptanoin Oral Liquid

ALBERTA

Ultragenyx Canada would like to announce that PrDOJOLVI<sup>®</sup> (triheptanoin) is eligible for public reimbursement in Alberta for patients with LC-FAOD through Alberta Blue Cross with [special authorization \(request form\)](#).

DOJOLVI<sup>®</sup> (triheptanoin) is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD).

Please consult the Product Monograph at [https://dojolvihcp.ca/wp-content/uploads/pdfs/Dojolvi\\_Final\\_PM.pdf](https://dojolvihcp.ca/wp-content/uploads/pdfs/Dojolvi_Final_PM.pdf) for important information on contraindications, warnings and precautions, the conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.

The Product Monograph is also available by calling us at 1-833-388-5872.

### **The DOJOLVI<sup>®</sup> Reimbursement Criteria for the [Alberta Drug Benefit List](#) Are as Follows:**

#### Special Authorization

For patients with an acute life-threatening long-chain fatty acid oxidation disorder (LC-FAOD) whose condition cannot be managed with conventional even-chain medium-chain triglyceride (MCT) supplementation. Treatment will be initiated in patients:

- with a confirmed diagnosis of LC-FAOD and who are experiencing acute life-threatening events\*  
OR
- without a confirmed diagnosis of LC-FAOD but who present with acute life-threatening events\* consistent with LC-FAOD

\* Acute life-threatening events consistent with LC-FAOD may include:

- A catastrophic presentation with acute or recurrent rhabdomyolysis with severe pain, compartment syndrome, acute renal failure requiring hospitalization and life-saving interventions including dialysis, treatment of hyperkalemia, and surgical treatment of compartment syndrome.
- Severe hypoglycemia, recurrent or acute with /without seizures
- Cardiomyopathy with or without arrhythmia

For coverage, this drug must be prescribed and monitored by a metabolic or genetic physician.

Information is required regarding the patient's response to conventional even-chain MCT supplementation.

Special authorization may be granted for 12 months.

Initial coverage is provided for post-hospital discharge only. For renewal of coverage, patients must show continued benefit from treatment with triheptanoin.

For more information on applying for DOJOLVI<sup>®</sup> coverage, we can arrange an appointment at your convenience, or you visit to the [UltraCare website](#). You can also find the [UltraCare Enrolment Form](#) on the UltraCare website.